LogicBio Therapeutics Revenue and Competitors

Claim your profile

Boston, MA USA



Total Funding



Estimated Revenue & Valuation

  • LogicBio Therapeutics's estimated annual revenue is currently $4M per year.(i)
  • LogicBio Therapeutics received $50.0M in venture funding in June 2017.
  • LogicBio Therapeutics's estimated revenue per employee is $65,000
  • LogicBio Therapeutics's total funding is $69M.

Employee Data

  • LogicBio Therapeutics has 62 Employees.(i)
  • LogicBio Therapeutics grew their employee count by -9% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation

We are a genome editing company developing genetic medicines for the fight against rare pediatric diseases. GeneRide is a promoterless and nuclease-free approach to gene insertion which may improve the safety profile of AAV based gene therapies With GeneRide, the therapeutic gene is site-specifically integrated into the genome allowing durable gene expression in dividing cells and mature tissues. Furthermore, therapeutic gene expression is regulated by the targeted locus so production can be limited to specific cell types.



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





LogicBio Therapeutics News

2022-04-20 - Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

LogicBio Therapeutics (NASDAQ:LOGC) shares are surging over 34% in pre-market trading this morning. NewAge (NASDAQ:NBEV) stock is climbing...

2022-04-13 - Critical Comparison: Voyager Therapeutics (NASDAQ:VYGR ...

This is a summary of recent recommendations for Voyager Therapeutics and LogicBio Therapeutics, as provided by MarketBeat.com. Sell Ratings...

2022-04-06 - LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Receives ...

LogicBio Therapeutics, Inc engages in the development of genome editing technology platform. It focuses on the commercialization of GeneRide,...

2021-05-05 - LOGICBIO THERAPEUTICS, INC. LogicBio Therapeutics : Announces Presentations at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

LEXINGTON, Mass. - LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, announced several preclinical data presentations, including an oral pre ...

2021-04-27 - ARIX BIOSCIENCE PLC LogicBio announces clinical and corporate updates

Arix Bioscience PLC (ARIX) LogicBio announces clinical and corporate updates 27-Apr-2021 / 14:00 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. =------------------------------------------------- ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

LogicBio Therapeutics Funding

DateAmountRoundLead InvestorsReference